Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
privosegtor
- Development stage
- Phase 3
- Lead developer
- Oculis
- Modality
- Modified Peptides → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Privosegtor (OCS-05) is a first-in-class neuroprotective peptoid small molecule (peptidomimetic) being developed for the treatment of neuro-ophthalmic and neurodegenerative disorders. Originally developed by Bionure (a spin-off from IDIBAPS and CSIC) and later licensed from Accure Therapeutics, the drug is designed to activate neurotrophic signaling pathways, thereby protecting retinal ganglion cells and the optic nerve from degeneration. Privosegtor is currently in late-stage clinical development for acute optic neuritis (AON), non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis relapses, with additional potential in glaucoma and geographic atrophy.
- Other names
- ACT-01ACT01ACT 01BN201BN-201BN 201OCS-05OCS05OCS 05
02
Targets
SGK2 (Serum/glucocorticoid regulated kinase 2)IGF-1R (Insulin-like growth factor 1 receptor)MDK (Midkine)
Beyond the preview
Go deeper on privosegtor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on privosegtor.